Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological options. The beneficial effects of relaxin peptide treatment were demonstrated in clinically relevant animal models of liver fibrosis. However, the use of relaxin is pro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:FASEB J
Egile Nagusiak: Kaftanovskaya, Elena M., Ng, Hooi Hooi, Soula, Mariluz, Rivas, Bryan, Myhr, Courtney, Ho, Brian A., Cervantes, Briana A., Shupe, Thomas D., Devarasetty, Mahesh, Hu, Xin, Xu, Xin, Patnaik, Samarjit, Wilson, Kenneth J., Barnaeva, Elena, Ferrer, Marc, Southall, Noel T., Marugan, Juan J., Bishop, Colin E., Agoulnik, Irina U., Agoulnik, Alexander I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Federation of American Societies for Experimental Biology 2019
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988856/
https://ncbi.nlm.nih.gov/pubmed/31419161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201901046R
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak